Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Eligible age
50+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.
Sponsor: The University of Texas Health Science Center at San Antonio
You may qualify if…
- ✓ Men and postmenopausal women aged 50 years or older.
- ✓ Body Mass Index (BMI) ≥30 kg/m².
- ✓ Untreated HbA1c \<6.5% at baseline.
- ✓ Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
- ✓ Able to provide informed consent and participate in all study assessments.
You may not qualify if…
- ✕ Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.
- ✕ Body Mass Index (BMI) ≥ 40 kg/m².
- ✕ Moderate to severe gastroesophageal reflux disease based on patient history.
- ✕ Inability to comply with the treatment protocol or to understand the consent form.
- ✕ Chronic Kidney Disease (CKD) Stage 4.
- ✕ Aspartate aminotransferase (AST) \> 33 U/L or alanine aminotransferase (ALT) \> 36 U/L.
- ✕ Active pregnancy.
- ✕ Personal or family history of medullary thyroid carcinoma.
Where it's recruiting
San Antonio
Source: ClinicalTrials.gov · NCT06811324 · last updated 2026-04-15